Figure S2 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

Lan V. Pham, Shengjian Huang, Hui Zhang, Jun Zhang,Taylor Bell,Shouhao Zhou,Elizabeth Pogue, Zhiyong Ding,Laura Lam, Jason Westin,R. Eric Davis,Ken H. Young,L. Jeffrey Medeiros,Richard J. Ford,Krystle Nomie,Leo Zhang,Michael Wang

crossref（2023）

引用 0|浏览2

暂无评分

摘要

Cell viability assays were performed using the Celltiter-Glo Luminescent Cell Viability Assay in representative MCL primary cells (PT-2 and PT-6) treated with increasing concentrations of ibrutinib (A) or idelalisib (B).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要